

Dr Fatme Mawas

Recent publications

Saydam M, Rigsby P & **Fatme Mawas F**. A novel Enzyme-Linked Immuno-Sorbent Assay (ELISA) for the quantification of total and free polysaccharide in Haemophilus influenzae b -tetanus toxoid conjugate vaccines in monovalent and combined vaccine formulations. *Biologicals* 2014, 42: 29-33.

Williams EJ, Lewis J, John T, Hoe JC, Yu L, Dongol S, Kelly DF, Griffiths DT, Shah A, Limbu B, Pradhan R, **Mawas F**, Shrestha S, Thorson SS, Werno AM, Murdoch DR, Adhikari N & Pollard AJ. Haemophilus influenzae type b carriage and novel bacterial population structure among children in urban Kathmandu, Nepal. *J. Clin. Microbiol.* 2011, 49(3):1323-1330.

Lancaster L, Saydam M, Markey K, Ho M.M. & **Mawas F**. Immunogenicity and physico-chemical characterisation of a candidate conjugate vaccine against group B streptococcus serotypes Ia, Ib and III. *Vaccine* 2011, 29(17):3213-3221.

Saydam M, Burkin K, Care R, Rigsby P, Bolgiano B & **Mawas F**. Immunogenicity and thermal stability of a combined vaccine against Haemophilus influenzae type b and Neisseria meningitidis serogroup C diseases. *Vaccines* 2010, 28 (38): 6228-6234.

Johnston L, **Mawas F**, Tierney R, Qazi O, Fairweather N & Sesardic D. Transcutaneous delivery of tetanus toxin Hc fragment induces superior tetanus toxin neutralizing antibody response compared to tetanus toxoid. *Human Vaccine*, 2009, 5(4): 230-236.

Mawas F, Ho MM & Corbel, MJ. Current progress with Moraxella catarrhalis antigens as vaccine candidates. *Expert Rev. Vaccines* 2009, 8 (1):77-90.

Bolgiano B, **Mawas F**, Burkin K, Crane DT, Saydam M, Rigsby P & Corbel MJ. A retrospective study on the quality of Haemophilus influenzae type b vaccines used in the UK between 1996 and 2004. *Hum. Vaccin.* 2007, 3 (5):176-182.

Mawas F, Ho MM, Huskisson R, Saydam M & Corbel, M.J. Physico-chemical characterisation and immunogenicity of a multi-valent candidate vaccine against non-typeable Haemophilus influenzae and Moraxella catarrhalis. *Vaccine* 2007, 25 (25): 4801- 4808.

Mawas F, Bolgiano B, Rigsby P, Crane D, Belgrave D & Corbel MJ. Evaluation of the saccharide content and stability of the first WHO International Standard for *Haemophilus influenzae* b capsular polysaccharide; *Biologicals*, 2007, 35(4):235-245.

Mawas F, Dickinson R, Douglas-Bardsley A, Xing DK, Sesardic D & Corbel MJ. Immune interaction between components of acellular pertussis-diphtheria-tetanus (DTaP) vaccine and Haemophilus influenzae b (Hib) conjugate vaccine in a rat model; *Vaccine*, 2006, 24(17): 3505-3512.

Mawas F, Peyre M, Beignon AS, Frost , Del Giudice G, Rappuoli R, Muller S, Sesardic D & Partidos CD. Successful induction of protective antibody responses against Haemophilus influenzae type b and diphtheria following transcutaneous immunization with the glycoconjugate PRP-CRM197

vaccine. *J. Infect. Dis.* 2004, 190:1177-1182.

Mawas F, Niggemann J, Jones C, Corbel MJ, Kamerling JP & Vliegenthart FGV. Immunogenicity of a conjugate vaccine made with a synthetic single repeating unit of type 14 pneumococcal polysaccharide coupled to CRM197: studies in a mouse model. *Infection & Immunity* 2002, 70 (9):5107-5114.

Ho-MM, **Mawas-F**, Bolgiano-B, Lemercinier-X, Crane-D, Huskisson-R and Corbel-MJ. Physico-chemical and immunological examination of the thermal stability of tetanus toxoid conjugate vaccines. *Vaccine*, 2002:3509-3522.

Bolgiano-B, **Mawas-F**, Yost-SE, Crane-DT, Lemercinier-X and , Corbel-MJ. Effect of physico-chemical modification on the immunogenicity of *Haemophilus influenzae* type b oligosaccharide-CRM197 conjugate vaccines. *Vaccine*, 2001; 19(23-24):3189-3200